Retrieve available abstracts of 13 articles: HTML format
Single Articles
July 2025
ELSAYED AMA, Kurose M, Higashiura A, Yamamoto A, et al Suppression of herpes simplex virus type 1 replication by Pin1 inhibitors:
insights from H-77 and novel compounds.
Antiviral Res. 2025;241:106244. PubMedAbstract available
March 2025
BIRKMANN A, Saunders R Overview on the management of herpes simplex virus infections: Current therapies
and future directions.
Antiviral Res. 2025;237:106152. PubMedAbstract available
November 2024
HU Z, Liu W, Liu J, Zhou H, et al The anti-tumor efficacy of a recombinant oncolytic herpes simplex virus mediated
CRISPR/Cas9 delivery targeting in HPV16-positive cervical cancer.
Antiviral Res. 2024 Nov 11:106035. doi: 10.1016/j.antiviral.2024.106035. PubMedAbstract available
August 2024
SZEMERE ZK, Murphy EA Import of extracellular 2'-3'cGAMP by the folate transporter, SLC19A1,
establishes an antiviral response that limits Herpes Simplex Virus-1.
Antiviral Res. 2024 Aug 16:105989. doi: 10.1016/j.antiviral.2024.105989. PubMedAbstract available
ZHENG S, Verjans GMGM, Evers A, van den Wittenboer E, et al CRISPR/Cas9-mediated genome editing of the thymidine kinase gene in a clinical
HSV-1 isolate identifies F289S as novel acyclovir-resistant mutation.
Antiviral Res. 2024;228:105950. PubMedAbstract available
June 2024
PEI J, Tian Y, Dang Y, Ye W, et al Flexible nano-liposomes-encapsulated recombinant UL8-siRNA (r/si-UL8) based on
bioengineering strategy inhibits herpes simplex virus-1 infection.
Antiviral Res. 2024;228:105936. PubMedAbstract available
CHEN SH, Damborsky JC, Wilson BC, Fannin RD, et al alpha7 Nicotinic Receptor Activation Mitigates Herpes Simplex Virus Type 1 Infection
in Microglia Cells.
Antiviral Res. 2024 Jun 14:105934. doi: 10.1016/j.antiviral.2024.105934. PubMedAbstract available
May 2024
EL-MAYET FS, Santos VC, Wijesekera N, Lubbers S, et al Glucocorticoid receptor and specificity protein 1 (Sp1) or Sp3, but not the
antibiotic Mithramycin A, stimulates human alphaherpesvirus 1 (HSV-1)
replication.
Antiviral Res. 2024;225:105870. PubMedAbstract available
November 2023
BERNSTEIN DI, Sawtell NM, Bravo FJ, Dixon DA, et al Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls
recurrent herpes disease and reduces reactivation of latent HSV.
Antiviral Res. 2023;219:105733. PubMedAbstract available
August 2023
GIORGI J, Simon B, Destras G, Semanas Q, et al Novel UL23 and UL30 substitutions in HSV1 and HSV2 viruses related to
polymorphism or drug resistance.
Antiviral Res. 2023;216:105672. PubMedAbstract available
July 2023
FENG Y, Yang Y, Zou S, Qiu S, et al Identification of alpha-linolenic acid as a broad-spectrum antiviral against
zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection.
Antiviral Res. 2023 Jul 8:105666. doi: 10.1016/j.antiviral.2023.105666. PubMedAbstract available
May 2023
CIVRA A, Costantino M, Ronchi G, Pontini L, et al Identification of oxysterol synthetic analogs as a novel class of late-stage
inhibitors of herpes simplex virus 2 replication.
Antiviral Res. 2023;215:105634. PubMedAbstract available
PACHOTA M, Grzywa R, Iwanejko J, Synowiec A, et al Novel inhibitors of HSV-1 protease effective in vitro and in vivo.
Antiviral Res. 2023;213:105604. PubMedAbstract available